Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Lu, Desheng ^a   Liu, Jerry X ^a   Endo, Tomoyuki ^a   Zhou, Haowen ^a   Yao, Shiyin ^a   Willert, Karl ^b   Schmidt Wolf, Ingo G H ^c   Kipps, Thomas J ^a   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA CATENIN; CYCLIN D1; ETACRYNIC ACID; FIBRONECTIN; KETONE; LYMPHOID ENHANCER FACTOR 1; WNT PROTEIN; FRIZZLED PROTEIN; FZD5 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; LEF1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; LEUKEMIA CELL; PROTEIN BINDING; REPORTER GENE; SIGNAL TRANSDUCTION; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; BETA CATENIN; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; DRUG SCREENING ASSAYS, ANTITUMOR; ETHACRYNIC ACID; FIBRONECTINS; FRIZZLED RECEPTORS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOID ENHANCER-BINDING FACTOR 1; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77954069621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008294     Document Type: Article

References (46)

1. Kipps TJ (1995) Chronic lymphocytic leukemia and related diseases. In: Beuter ELM, Coller B, Kipps TJ, eds. Williams Hematology. 5 ed. New York: McGraw-Hill, Inc. pp 1017-1039.
2. Caligaris-Cappio F, Hamblin TJ (1999) B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17: 399-408.
3. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, et al. (2002) Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). pp 193-213.
4. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, et al. (2003) Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). pp 153-175.
5. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
6. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
7. Nusse R (2005) Wnt signaling in disease and in development. Cell Res 15: 28-32.
8. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
9. Willert K, Jones KA (2006) Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404.
10. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101: 3118-3123.
11. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647.
12. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, et al. (2007) Gene expression profiling of B lymphocytes and plasma cells from Walden- strom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21: 541-549.
13. Lambert E, Rees JK, Twentyman PR (1992) Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay. Leukemia 6: 1063-1071.
14. Twentyman PR, Lambert E, Muller M, Rees JK (1992) Selective toxicity of ethacrynic acid towards lymphocytes of chronic lymphocytic leukemia in vitro. Leukemia 6: 726-728.
15. Tew KD, Bomber AM, Hoffman SJ (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625.
16. Tew KD, Dutta S, Schultz M (1997) Inhibitors of glutathione S-transferases as therapeutic agents. Adv Drug Deliv Rev 26: 91-104.
17. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M, et al. (2003) Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94: 886-893.
18. Jin G, Lu D, Yao S, Wu CC, Liu JX, et al. (2009) Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival. Bioorg Med Chem Lett 19: 606-609.
19. Lu D, Cottam HB, Corr M, Carson DA (2005) Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 102: 18567-18571.
20. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452.
21. Willert KH (2008) Isolation and application of bioactive Wnt proteins. Methods Mol Biol 468: 17-29.
22. Hermanson GT (1996) Bioconjugate Techniques. San Diego: Academic Press. pp 467-469.
23. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF (2002) Wnt-3A/beta- catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 277: 33398-33410.
24. Gradl D, Kuhl M, Wedlich D (1999) The Wnt/Wg signal transducer beta- catenin controls fibronectin expression. Mol Cell Biol 19: 5576-5587.
25. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, et al. (2001) Beta- catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53-57.
26. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96: 5522-5527.
27. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
28. Porfiri E, Rubinfeld B, Albert I, Hovanes K, Waterman M, et al. (1997) Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. Oncogene 15: 2833-2839.
29. Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, et al. (2000) Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13: 15-24.
30. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105: 3047-3052.
31. Howe D, Bromidge T (2006) Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk Res 30: 29-32.
32. Love JJ, Li X, Case DA, Giese K, Grosschedl R, et al. (1995) Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376: 791-795.
33. Caricasole A, Ferraro T, Iacovelli L, Barletta E, Caruso A, et al. (2003) Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem 278: 37024-37031.
34. Cavodeassi F, Carreira-Barbosa F, Young RM, Concha ML, Allende ML, et al. (2005) Early stages of zebrafish eye formation require the coordinated activity of Wnt11, Fz5, and the Wnt/beta-catenin pathway. Neuron 47: 43-56.
35. He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, et al. (1997) A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275: 1652-1654.
36. Sercan HO, Pehlivan M, Simsek O, Ates H, Sercan Z (2007) Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines. Oncol Rep 18: 1563-1569.
37. Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, et al. (1992) Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80: 2038-2043.
38. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, et al. (2006) Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13: 748-758.
39. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 2200-2206.
40. Horie R, Watanabe M, Okamura T, Taira M, Shoda M, et al. (2006) DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20: 800-806.
41. Han Y, Englert JA, Delude RL, Fink MP (2005) Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway. Shock 23: 45-53.
42. Wang R, Li C, Song D, Zhao G, Zhao L, et al. (2007) Ethacrynic acid butyl- ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition. Cancer Res 67: 7856-7864.
43. Schmidt M, Sievers E, Endo T, Lu D, Carson D, et al. (2009) Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144: 796-798.
44. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 104: 7516-7521.
45. Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, et al. (1994) Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther 270: 1186-1191.
46. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, et al. (1991) Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 6059-6065.